Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer

Lung Cancer

Volumn 83, Issue 2, 2014, Pages 219-223

  Stephenson, Joe J ^a   Nemunaitis, John ^b   Joy, Anil A ^c   Martin, Julie C ^a   Jou, Ying Ming ^d   Zhang, Da ^d   Statkevich, Paul ^d   Yao, Siu Long ^d   Zhu, Yali ^d   Zhou, Honghong ^d   Small, Karen ^d   Bannerji, Rajat ^d,f   Edelman, Martin J ^e,g  

^a Institute for Translational Oncology Research   (United States)

^b Mary Crowley Cancer Research Centers   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d MERCK RESEARCH LABORATORIES   (United States)

^e UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^f ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

CDK inhibitor; Dinaciclib; Erlotinib; Monotherapy; NSCLC; Phase 2

Indexed keywords

DINACICLIB; ERLOTINIB; MK 7965; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; EMPYEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOLOGICAL PARAMETERS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; TIME; TIME TO PROGRESSION; TREATMENT RESPONSE; VERY ELDERLY;

CDK INHIBITOR; DINACICLIB; ERLOTINIB; MONOTHERAPY; NSCLC; PHASE 2;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BICYCLO COMPOUNDS, HETEROCYCLIC; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PYRIDINIUM COMPOUNDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84892865722     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.11.020     Document Type: Article

References (13)

1. Parry D., Guzi T., Shanahan F., Davis N., Prabhavalkar D., Wiswell D., et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther 2010, 9:2344-2353.
2. Abdullah C., Wang X., Becker D. Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma. Cell Cycle 2011, 10:977-988.
3. Feldmann G., Mishra A., Bisht S., Karikari C., Garrido-Laguna I., Rasheed Z., et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011, 12:598-609.
4. Fu W., Ma L., Chu B., Wang X., Bui M.M., Gemmer J., et al. The cyclin-dependent kinase inhibitor SCH 727965 (dinaciclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 2011, 10:1018-1027.
5. Mita M.M., Mita A.C., Moseley J., Poon J., Small K.A., Jou Y., et al. A phase I study of the CDK inhibitor dinaciclib (SCH727965) administered every 3 weeks in patients (pts) with advanced malignancies: final results. J Clin Oncol 2011, 29. Abstract 3080.
6. Nemunaitis J.J., Small K.A., Kirschmeier P., Zhang D., Zhu Y., Jou Y.M., et al. A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Transl Med 2013, 11:259.
7. TARCEVA®(erlotinib) Package insert 2012, Genentech USA, Inc., South San Francisco, CA.
8. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. National Cancer Institute of Canada Clinical Trials G. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
9. Thall P.F., Wooten L.H., Tannir N.M. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials 2005, 2:467-478.
10. Nemunaitis J., Saltzman M., Rosenberg M.A., Khaira D., Small K., Kirschmeier P., et al. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of SCH 727965, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. J Clin Oncol 2009, 27. Abstract 3535.
11. Bates D.J., Salerni B.L., Lowrey C.H., Eastman A. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis. Cancer Biol Ther 2011, 12:314-325.
12. Anagnostou V.K., Lowery F.J., Zolota V., Tzelepi V., Gopinath A., Liceaga C., et al. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10:186.
13. Booher R., Hirsch H., Strack P., Zawel L., Fawell S. Mcl-1 dependency is a predictive biomarker for apoptotic induction by short-term dinaciclib (SCH 727965) treatment. Cancer Res 2012, 72. Abstract 3063.